SMN2 and spinal muscular atrophy: Spinraza, an ASO approved for spinal muscular atrophy, alters the splicing of survival motor neuron 2 (SMN2) pre-mRNA to increase the production of functional SMN protein, significantly improving patient outcomes (Mercuri et al., 2018).